Background
Abstract Background
Several countries or regions within countries have an effective national asthma strategy resulting in reduction of the large burden of asthma to individuals and society. There has been no systematic appraisal of the extent of national asthma strategies in the world.
Methods
The Global Asthma Network (GAN) undertook an email survey of 276 principal investigators of GAN centres in 120 countries, in 2013-2014. One of the questions was: asthma strategy been developed in your country for the next five years? For children? For .
Results
Investigators in 112 (93.3%) countries answered this question. Of these, 26 (23.2%) reported having a national asthma strategy for children and 24 (21.4%) for adults; 22 (19.6%) countries had a strategy for both children and adults; 28 (25%) had a strategy for at least one age group. In countries with high prevalence of current wheeze strategies were significantly more common than in low prevalence countries (11/13 (85%) and 7/31 (22.6%) respectively, p<0·001).
Interpretation
In 25% countries a national asthma strategy was reported. A large reduction in the global burden of asthma could be potentially achieved if more countries had an effective asthma strategy.
Introduction
Asthma is a common chronic disease affecting an estimated 241 million children and adults in the world according to the estimates of the Global Burden of Disease 2013 (1), which also . estimated that asthma was the 15th highest ranked cause of Years Lived with Disability (1). Many people with asthma are unnecessarily disabled, because they are not receiving optimal asthma management (2). In 2013, it was estimated that about 22 million disability-adjusted life years are lost because of asthma (3). The International Study of Asthma and Allergies in Childhood (ISAAC) found that the historical view of asthma being a disease of high-income countries (HICs) no longer holds: most people affected are in lowand middle-income countries (LMICs), and asthma prevalence is estimated to be increasing fastest in those countries (4) To reduce the burden of asthma, several HICs and LMICs have developed an asthma strategy (or an asthma programme which is the terminology used by some countries) at a national or regional level which have resulted in rapid reduction of the ill-effects of asthma (5). The strategies or programmes are formalised with political engagement and commitment. Implementation of such strategies includes relatively simple measures which are consistently applied in the relevant population, to improve early detection of asthma and provide access to effective anti-inflammatory treatment. Extension of this approach to other countries or regions within countries could be of great potential benefit to reducing the burden of asthma in the world.
The first comprehensive national asthma strategy was developed in Finland in 1994 and has served as a model for other countries. They developed and called it a comprehensive nationwide Asthma Programme and over the next decade this lessened the burden of asthma on individuals and society and more than halved the total asthma costs (healthcare, drugs, disability, and productivity loss) (6, 7) and these benefits have continued (8). This model was followed several years later by several other national strategies within the European Union (9) including France (10), Portugal (11), and Spain (12). In other places, independent approaches have been used with improved outcomes, including Australia (13), the city of Salvador, Brazil (14), Canada (15), Costa Rica (16), Singapore (17), Tonga (18) and Turkey (19).
However, there are few reports of such strategies, suggesting that in many countries there is no strategy or it has not been implemented. However there has been no systematic appraisal of the numbers of countries in the world which have a national asthma strategy. building and access to quality-assured essential medicines. Given the large number of centres and countries involved with GAN, it was well placed to undertake such a survey.
Based on the low number of national asthma strategies reported in the literature, our hypothesis was that most countries in the world do not have a national asthma strategy.
survey to be undertaken to answer a question about whether a country had a national asthma strategy for children and adults.
Materials and Methods
A cross-sectional survey of GAN centres was carried out between April 2013 and July 2014. Where conflicting answers were given by two or more investigators from different centres within a country, the GAN Global Centre staff entered into a discussion via email with the centre investigators until agreement between them was reached.
Country findings were compared with the prevalence of asthma symptoms in 13-14 year olds in countries where this had been estimated in ISAAC Phase Three (22). Countries were categorised as high prevalence if the prevalence of current wheeze was >20%, and low prevalence if the prevalence of current wheeze was <10%. The relationship of national asthma strategies to changes in country prevalence of asthma symptoms in 13-14 year olds in countries where this had been estimated in ISAAC Phase Three (4) was also examined .  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65 The data were entered into an excel spreadsheet and checked for apparent inconsistencies which were reconciled if appropriate. Simple descriptive analyses were undertaken. The Chi-Squared test was used to compare responses about strategies between LMICs and HICs, (23).
Results
Of the 276 centre principal investigators in 120 countries, 213 (77.2%) investigators in 112 (93.3%) countries completed the national asthma strategy question. There were no responses from any investigators in eight countries who were approached: three HICs and five LMICs.
Conflicting answers were obtained from two or more centres in 16 countries, and agreement was subsequently reached. Of the 112 countries, 43 (38.4%) were HICs including 48.3% of 69 (61.6%) were LMICs including 48.2 (Table) .
Of those 112 countries where the national asthma strategy questions were answered for seven in HICs and five in LMICs. For adults, 16 reported , 11 in HICs and five in LMICs.
Of the 112 countries, 26 (23.2%) reported a national asthma strategy for children, 24 (21.4%) reported a national asthma strategy for adults, and 22 (19.6%) countries had strategies for both children and adults. Twenty-eight (25%) had a national asthma strategy for at least one age group. These are illustrated in the Figure. Of the 28 countries who reported a national asthma strategy for at least one age group 15 (53.6%) were HICs and 13 (46.4%) LMICs. Strategies were reported in 15/43 (34.9%) HICs and 13/69 (18.8%) LMICs; these differences were not significant p=0·057.
In 81/112 (72%) countries the prevalence of asthma symptoms had been estimated in ISAAC. Any national asthma strategy was significantly more common in countries with high prevalence of current wheeze (>20%) than low prevalence (<10%): 11/13 (85%) and 7/31 (22.6%) respectively, p<0·001, with the remaining 37 countries having prevalence 10-20%.
Of the 49 countries in whom time-trends in the prevalence of asthma symptoms had been estimated in ISAAC, any national asthma strategy was equally common in those whose prevalence rose (11/30) and in those in whom it fell (6/19) p=0·72. 3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65 In this email confirm our hypothesis that most countries in the world do not have a national asthma strategy; only about one in four countries reported that they had a national asthma strategy. Of potential concern was that the proportion of LMICs with a strategy was lower than HICs, although this was not statistically significant.
Discussion
About three in four countries surveyed by GAN had the prevalence of asthma symptoms measured in ISAAC, and of these, having a national asthma strategy was significantly more common in countries with high prevalence compared with low prevalence of current wheeze.
While on the face of it this seems logical more asthma symptoms, more concern to take action to address the issue -there are three caveats. Firstly, many of the countries with a low prevalence of asthma symptoms and no national asthma strategy have very large populations; for example Brazil, China, Indonesia, Mexico, Philippines each of which has >100 million people and is among the top 12 most populous countries in the world in 2015 (24). Small improvements in the management and outcomes for people with asthma in each of these countries would have a relatively big impact on the global numbers of people burdened by asthma. Secondly, in this survey one in four countries had not measured their asthma prevalence, which illustrates either their lack of interest in asthma or perhaps they had experienced difficulties engaging in world-wide epidemiological studies. Thirdly, the ISAAC data is already 13 years old (2002-3) and thus not coincident with this survey, so the interpretation needs caution.
This is a very large study, a high response rate of 93% was achieved, data was reported from 112 countries LMICs. The response rate was high because of the close relationship between the GAN Global Centre and GAN Principal Investigators.
The recommended components of a successful national asthma strategy include: government commitment, policies and legislation (e.g. tobacco reduction), management by the health ministry, funding and capacity building, registry of outcome data before and after implementation (prevalence, severity, asthma control, hospitalisations, mortality), asthma management guidelines adjusted for the country, access to medical care and qualityassured, affordable, essential asthma medicines available for everyone with asthma, education of the public, continued education of health professionals, economic analyses, process and outcome evaluation, follow-up programmes, and continued asthma research (5, 9) . 3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65 There may be differe . National asthma management guidelines alone should not be considered a national asthma strategy or programme, although they form an essential part. In this particular survey national asthma management guidelines alone were unlikely to be confused with strategy, because they were asked about in the preceding seven questions in the survey. However, the survey is likely to have missed asthma strategies which were not country-wide; these would be more likely in a very large country like Brazil or China. Additionally, some national asthma programmes may not have strategies for the purpose of this survey.
In the review of national and regional asthma strategies in Europe (9), a systematic search of the English literature in 2014 found only eight published national and regional asthma strategies in European Union countries: Finland (7), France, Ireland, Italy, The Netherlands, Lodz area of Poland, whole of Poland and Portugal (11), with only three strategies having been evaluated (Finland, Poland, Portugal) . Outside the European Union, asthma strategies have been identified from only eight other countries (13) (14) (15) (16) (17) (18) (19) 25) .
There are likely to be many reasons for the low level of publication of national asthma strategies where they exist, including poor preparation with insufficient documentation, dissemination, implementation or evaluation, lack of appropriate training of primary health care professionals in diagnosis and treatment, poor access to quality assured, essential asthma medicines, poor outcomes, unable to prepare an article for publication in English, and publication bias. The absence of a national asthma strategy may reflect that asthma is not recognised as a serious public health problem, a lack of asthma prevalence, severity and mortality data, a lack of government prioritisation of asthma among other non-communicable diseases, lack of national health coordination, and/or a lack of government commitment to improving national health issues.
Not all national asthma strategies have been successful. Selroos and others have suggested that good results can also be achieved without a formal national asthma strategy, as long as evidence-based management guidelines are implemented and widely used (9). This is happening, for example, in Sweden, where recommendations (in Swedish) for diagnosis and treatment have been issued and updated by the National Board of Health and Welfare (26).
The Swedish Asthma and Allergy Foundation has recently issued a comprehensive national strategy document. It has been estimated that global asthma deaths (all ages) reduced from 504,300 in 1990 to 489,000 in 2013 (27), but many countries do not report asthma deaths separately (28). In Europe asthma mortality decreased from 6441 to 1164 cases (82%) from 1990-2012 (29) . 3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65 In 2009, a group of experts in asthma care, the Advancing Asthma Care Network, reviewed asthma projects and strategies in Argentina, Australia, Brazil, China, Japan, Mexico, the Philippines, Russia, South Africa, and Turkey (30). All successful asthma strategies improved early diagnosis and the introduction of first-line treatment with anti-inflammatory medication, improved long-term disease control nationally, introduced simple means for guided self-management to proactively prevent exacerbations/attacks, and had effective education and networking with general practitioners, nurses and pharmacists. A systematic approach was recommended, aiming to motivate and organise, and improvements which could be achieved with relatively simple means. When multidisciplinary actions are being planned, all the main stakeholders should be represented.
A more limited approach to improving asthma outcomes has been used successfully in pilot projects in LMICs, using standard case management Lung Health and essential asthma medicines free of charge, the number of patients being referred from primary to secondary or tertiary level dropped by 60%, with greater convenience for patients, and savings for health services.
Political engagement, leadership and commitment are key components for developing an effective national asthma strategy, and these are challenging and may not be easily achieved. The literature supports the view that programmes (strategies) are more likely to be successful where this has occurred. The political organisation and health leadership in a country would undoubtedly influence the chance of success, as would co-ordinated access to affordable, quality-assured, essential asthma medicines. Identifying a political champion is a critical factor, and may be easier in some localities than others. In 2010 the Global Initiative for Asthma (GINA) launched a challenge to countries to reduce hospitalisations by 50% over 5 years (36) but the results have been modest. The motivation to tackle the asthma burden is not always self-evident, e.g. in places where private health-care dominates and hospitals compete.
In this survey we asked only about national asthma strategies, not local or regional strategies. We know that there have been successful strategies in cities such as Salvador, We recommend that health authorities along with governments in all countries should develop national asthma strategies with associated national action plans to improve early detection of asthma and subsequently improve asthma management and reduce costs (5).
Such strategies should be evaluated, reported, and published. The problems to be addressed may be different in HICs compared to LMICs, and the solutions need to be tailored according to local needs, resources and organisation.
Knowledge of asthma prevalence and severity and changes over time is fundamental to understanding the burden of asthma within each country and thus leading to the development of a national asthma strategy. This can be achieved using the methodology developed by ISAAC (38, 39) and continued (expanded to include adults) under GAN (40).
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